Ryne Sandberg Shares Details on Prostate Cancer Relapse
Former Chicago Cubs player Ryne Sandberg recently took to social media to share a devastating update regarding his health with his fans. The ex-MLB second baseman first shocked the sporting world in January 2024 when he revealed that he was suffering from metastatic prostate cancer.
Cubs legend Ryne Sandberg shares prostate cancer relapse
Baseball Hall of Famer and Chicago Cubs icon Ryne Sandberg announced on Dec. 10 that his prostate cancer has relapsed and spread to other organs. Sandberg shared the update on Instagram, saying he has resumed intensive treatment and remains determined to fight the disease.
By Dr. Priyom Bose, Ph.D. A comprehensive review highlights the progress, challenges, and future prospects of prostate cancer ...
Montell Jordan is advocating for prostate cancer awareness and emphasizing the importance of early detection, particularly ...
Shares of Candel Therapeutics took flight in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a late-stage study of its CAN-2409 product candidate met its key goal ...
A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The ...
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...
Treatment with five-fraction SBRT could be effective versus traditional radiation in certain patients with low- or ...
Adoption of active surveillance or watchful waiting has been increasing among patients with intermediate-risk prostate cancer ...
Investigators assessed the oncologic benefit of salvage radiation therapy versus observation for men with biochemical recurrence after radical prostatectomy.
Sky Sports is supporting The BIGGER 180 campaign; in the UK, one man dies from prostate cancer every 45 minutes but finding ...
Candel Therapeutics said on Wednesday its experimental prostate cancer drug met the main goal of a late-stage trial, sending the company's shares up 64% in premarket trading.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback